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Furthermore, there was a highly significant correlation between 
incorporated 3H-proline at day 4 and the PIINP release at day 15 
(r =0.94, p<0.0083). 
Conclusions: These preliminary findings indicate that the pro- 
posed assay is able to detect and monitor changes in collagen 
type II formation, suggesting that the assay carries noteworthy 
potentials as a biomarker of cartilage formation in experimental 
settings. 
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Introduction: Decorin, biglycan, fibromodulin and lumican are all 
SLRPs involved in maintaining the integrity of cartilage and inter- 
vertebral disc (IVD) matrix. Recently, we discovered that, kerato- 
can was present at the protein level in extracts of osteoarthritc 
(OA) articular and degenerative disc tissues. The object of this 
study has been to investigate the presence of lumican and kera- 
tocan in extracts of OA cartilage and age matched normal carti- 
lage and from scoliosis (normal) and pathologic disc tissue. This 
objective has been carried out using newly characterised mono- 
clonal antibodies (mAbs) in Western blot analysis to qualitatively 
examine the protein levels of these SLRPs and at RNA level using 
conventional RT-PCR methodologies. Our working hypothesis is 
that as a result of degenerative processes there is increased ex- 
pression of these two SLRPs both at the protein and RNA level 
that could be due to the reparative deposition of a type I collagen 
fibrillar 'scar'. 
Methods: mAbs were produced to core protein epitopes in lumi- 
can and keratocan. OA cartilage was obtained from patients un- 
dergoing routine joint replacement for either hip or knee joints, 
whilst age controlled normal cartilage was obtained from pa- 
tients undergoing hip hemiarthroplasty. Disc samples were ob- 
tained from patients undergoing a variety of spinal procedures 
and Graded I-V according to Pfirrmann et al. The tissue was diced 
and extracted in a 4M guanidine HCI buffer, pH6.8 containing an 
inhibitor cocktail for 48 h at 4°C. Samples were dialysed exhaus- 
tively against Milli Q water and assayed for glycosaminoglycan 
(GAG) content using the DMMB assay. Extracts containing equal 
amounts of GAG were separated by SDS-PAGE and transferred 
to nitrocellulose for Western blotting using mAbs to either kerato- 
can or lumican. RNA purification was achieved using the Qiagen 
RNA kit and isolated RNA was quantified at 260/280 nm. Equal 
amounts of RNA (50-500 ng) were used to generate cDNA (RT 
reaction). Primers specific for keratocan or lumican were used for 
PCR analysis. 
Results: Keratocan was only detected at the protein and mRNA 
level in OA cartilage but it was detected both in normal and de- 
generate IVD samples. Lumican was present in normal and OA 
cartilage. However, the presence of this SLRP was substantially 
increased in the OA cartilage extracts. PCR analysis showed 
mRNA levels to be similar in normal and diseased tissue. Lu- 
mican was also present in extracts of IVD with an increase being 
apparent in those disc samples with pathology. In contrast o OA 
cartilage message levels for lumican appeared to be increased in 
the degenerate disc samples analysed. 
Discussion: The unexpected increase in the detection of protein 
for keratocan and lumican in degenerative articular cartilage and 
disc suggests their potential as biomarkers for the onset of joint 
and disc disease. Future work will involve the development of a 
quantitative assay for these proteins and the investigation of the 
presence of these molecules in synovial fluid and serum. 
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Aim: To evaluate concentrations of serum biomarkers of type II 
collagen degradation (C2C) and synthesis (CPII) in a guinea pig 
model of spontaneous osteoarthritis (OA). 
Methods: Two strains of guinea pigs were examined in this study: 
1) the Hartley (OA-prone, aged 2, 4, 7, 10 and 12 months) and 
Strain 13 (OA-resistant, aged 3 and 12 months). All animals were 
acclimated to housing conditions for one week prior to sample 
collection. Blood was obtained from guinea pigs under isofluo- 
rane anesthesia, centrifuged at 3500 rpm for 10 minutes and 
serum stored in 1 ml aliquots at -80°C until analyzed. Knee joints 
were prepared for histological grading and a semi-quantitative 
system was used to evaluate OA severity. Serum biomarkers, 
C2C and CPII were quantified using commercially available kits 
from IBEX (Montreal, CAN). Statistical analyses were performed 
and a p-value of < 0.05 was considered statistically significant. 
Results: Serum C2C and CPII concentrations were similar for 
Hartley and Strain 13 animals at 2 months of age (n=3 each), 
prior to any evidence of histological OA. However, at 12 months 
of age, levels of serum C2C were significantly higher, and levels 
of CPII were significantly lower, in the Hartley guinea pig com- 
pared to the age-matched Strain 13 animals (n=8 each, p<0.01 
and p<0.05, respectively). The ratio of C2C/CPII was also signif- 
icantly higher in the Hartley strain compared to the age-matched 
Strain 13 (p<0.001). Levels of C2C as well as the C2C/CPII ratio 
correlated positively with histological damage in the medial com- 
partment, and correlated specifically to degeneration of cartilage 
structure (p=0.009, r=0.647 and p=0.014, r=0.617, respectively). 
A cross-sectional analysis of Hartley guinea pigs from ages 3- 
12 months demonstrated that C2C and C2C/CPII concentrations 
were consistently higher than concentrations in 12 month-old 
Strain 13 animals, while CPII concentrations were consistently 
lower than Strain 13. Interestingly, C2C correlated with CPII from 
4-12 months of age (r=0.48, p=0.02). However, within the Hartley 
strain alone, the biomarker concentrations for these collagen II 
markers did not correlate with histological scores. 
Conclusions: In both animal and human studies, researchers 
continue efforts to identify useful biomarkers that are disease 
specific, reflect disease progression, and are sensitive to change 
due to therapeutic interventions. Serum C2C and CPII are sys- 
temic markers indicative of overall metabolism of type II collagen. 
In humans, the ratio of these biomarkers correlates positively with 
risk of OA progression. In the guinea pig, a higher C2C/CPII ra- 
tio was observed for the OA-prone Hartley relative to the OA- 
resistant Strain 13. Taken together with the fact that C2C was 
positively correlated with CPII, these data reflect an upregulation 
and imbalance of collagen II degradation and synthesis in the 
OA-prone Hartley guinea pig. We previously described that the 
Hartley also displays high bone turnover. These data support the 
hypothesis that metabolic factors influencing bone and cartilage 
metabolism appear to be specific hallmarks of the development 
and progression of OA in the Hartley guinea pig. 
